Guerbet
Guerbet is a global leader in medical imaging, specializing in the research, development, manufacturing, and marketing of contrast agents for diagnostic imaging. Founded in 1926, the company has a rich history that began with the discovery of the first iodinated organic contrast medium, Lipiodol. Guerbet's product portfolio includes contrast agents for X-ray, computed tomography (CT), and magnetic resonance imaging (MRI), with notable products like Elucirem, an MRI contrast agent approved by the U.S. FDA in 2022. The company is committed to digital innovation, collaborating with IBM Watson Health to develop AI solutions that enhance cancer diagnosis and care. With over 2,700 employees and manufacturing sites across several countries, Guerbet operates globally, providing high-quality contrast agents to hospitals, diagnostic imaging centers, and healthcare professionals. Their products support a variety of clinical applications, ensuring accurate diagnosis and improved patient care in the healthcare market.
Work at Guerbet in HR or recruiting? Claim this page
Headcount trend
Guerbet went from 799 employees in Oct 2024 to 773 in Sep 2026. Apr to Sep 2026: 23 people joined, 14 left.
Org structure
Headcount by department
H-1B sponsorship
Peer reviews
Worked with someone at Guerbet?
Anonymous peer reviews on OffTheRecord
Hiring now
Similar companies
Guerbet FAQ
How many employees does Guerbet have?
Guerbet has about 773 employees, up 1% over the 3 months to Sep 2026.
Does Guerbet sponsor H1B visas?
Yes. Guerbet filed 1 H1B (LCA) application in FY2026, according to the latest U.S. Department of Labor disclosures. It was for a Executive role.
What is Guerbet's revenue per employee?
Guerbet makes about $1.15M in revenue per employee, based on $886.72M annual revenue and 773 employees.
Is Guerbet a public company?
Yes. Guerbet is publicly traded under the ticker GBT.PA on PAR.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.